Taken together, these results suggest that the anti-MF-CADM1-specific antibodies may be useful not only for identifying the functional role and relevance of MF-CADM1 in SCLCs but also for developing the next-generation SCLC therapeutics for antibody therapy. Here, CADM1 is linked to small cell lung carcinoma.